Results 121 to 130 of about 409,524 (305)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Single-cell and bulk RNA sequencing analysis reveals CENPA as a potential biomarker and therapeutic target in cancers.

PLoS ONE
BackgroundCancer remains one of the most significant public health challenges worldwide. A widely recognized hallmark of cancer is the ability to sustain proliferative signaling, which is closely tied to various cell cycle processes. Centromere Protein A
Hengrui Liu, Miray Karsidag, Kunwer Chhatwal, Panpan Wang, Tao Tang   +4 more
doaj   +1 more source

Expression of Programmed Death Ligand-1 in Head and Neck Squamous Cell Carcinoma: A Cross-sectional Study [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Head and Neck Squamous Cell Carcinoma (HNSCC) is among the most prevalent malignancies worldwide, with poor survival outcomes despite advances in multimodal therapy.
Shivani Bhargava, Monika Kalyan, Nisha Marwah, Simran Yadav, Sumiti Gupta, Sunita Singh   +5 more
doaj   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Identifying Potential Effective Diagnostic and Prognostic Biomarkers in Sepsis by Bioinformatics Analysis and Validation

International Journal of General Medicine, 2022
Xu Huang, Jixiang Tan, Xiaoying Chen, Lin Zhao Department of Intensive Care Unit, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of ChinaCorrespondence: Lin Zhao, Department of Intensive Care Unit, The First ...
Huang X, Tan J, Chen X, Zhao L
doaj  

Prognostic Biomarkers in Head and Neck Cancer [PDF]

Clinical Cancer Research, 2006
Most of the cancers that arise in the mucosa of the upper aerodigestive tract, including the oral cavity, pharynx, and larynx, are squamous cell carcinomas. To date, although there are no primary mutations that have been discovered to cause these cancers, aberrant expression of a variety ...
openaire   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Bioinformatics Analysis of KIF1A Expression and Gene Regulation Network in Ovarian Carcinoma

International Journal of General Medicine, 2021
Xiaoyuan Lu,1,* Guilin Li,2,* Sicong Liu,3 Haihong Wang,1 Zhengzheng Zhang,1 Buze Chen1,4 1Department of Gynecology, The affiliated Hospital of Xuzhou Medical University, Xuzhou, 221000, Jiangsu, People’s Republic of China; 2Department of ...
Lu X, Li G, Liu S, Wang H, Zhang Z, Chen B   +5 more
doaj  

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source